Physician profile
Frank Savoretti
NPI 1750377149
$1,420.05
in general payments reported to CMS, 2019-2025
18 companies · $628 in 2025
The $628 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $30.53 · 2021: $99.84 · 2023: $84.38 · 2024: $577 · 2025: $628.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,290.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,289.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $343.18 | 2024-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $222.88 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $163.38 | 2024-2025 | Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $147.31 | 2019-2025 | Jardiance, Tradjenta |
| Gilead Sciences, INC. | $99.84 | 2021 | |
| Exact Sciences Corporation | $69.85 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Aimmune Therapeutics, INC. | $60.62 | 2024 | |
| Abbvie INC. | $59.36 | 2023-2025 | Ubrelvy |
| Pfizer INC. | $52.28 | 2024-2025 | |
| Amgen INC. | $48.72 | 2024-2025 | Evenity, Repatha, Otezla |
| Inspire Medical Systems, INC. | $37.85 | 2025 | Inspire |
| Baxter Healthcare | $21.76 | 2024 | Hillrom - Cardiac Ambulatory Monitor |
| Actelion Pharmaceuticals US, INC. | $17.53 | 2025 | Uptravi, Opsumit |
| Supernus Pharmaceuticals, INC. | $15.98 | 2023 | Qelbree |
| Genentech USA, INC. | $15.63 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $15.25 | 2024 | |
| Sumitomo Pharma America, INC. | $15.11 | 2025 | Gemtesa |
| Sage Therapeutics, LLC | $13.52 | 2025 | Zurzuvae |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Savoretti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.